COVID-19 Drugs
- * HELP ! - Expert help urgently needed. Please email us links on relevant papers. 260698
- Covid-19: What is the evidence for the antiviral molnupiravir? - BMJ 13.04.22 284069
- WHO prequalifies first monoclonal antibody - tocilizumab – to treat COVID-19 - WHO 11.02.22 274861
- Covid-19: Molnupiravir effects - Buyer beware: molnupiravir may damage DNA - BMJ 04.11.21 261899
- How antiviral pill molnupiravir shot ahead in the COVID drug hunt - nature 08.10.21 257660
- Nanotechnology offers alternative ways to fight COVID-19 pandemic with antivirals - nature 07.10.21 257873
- Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER)... - The Lancet 01.09.21 259489
- Humanigen Reports Positive Phase 3 Topline Results Demonstrating That Lenzilumab™ Improves Survival Without Need for Mechanical Ventilation in Hospitalized Patients With COVI… 251474
- Progesterone therapy may improve COVID-19 outcomes for men, study finds - Science Daily 18.03.21 251505
- COVID antibody treatments show promise for preventing severe disease - Nature 12.03.21 247415
- Could Efforts to Fight the Coronavirus Lead to Overuse of Antibiotics? - PEW 10.03.21 247424
- * Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): preliminary results of a randomised, controlled, open-label, platform trial - medRXiv 11.02.21 235009
- Covid-19: Arthritis drug tocilizumab reduces deaths in hospitalised patients, study shows - BMJ 11.02.21 247416
- Covid-19 controversies: the tocilizumab chapter - BMJ 27.01.21 235945
- Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial - BMJ 20.01.21 247417
- Azithromycin in Hospitalised Patients with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial - MedRxiv 10.12.20 228315
- Dexamethasone in hospitalised patients with COVID-19: addressing uncertainties - Lancet, Respiratory Medicine 29.10.20 229583
- Understanding the Benefits and Limitations of Remdesivir: A Closer Look at the First FDA-Approved Drug for Covid-19 - VaxTherapy 27.10.20 247418
- The race to make COVID antibody therapies cheaper and more potent - nature 23.10.20 221733
- Remdesivir and interferon fall flat in WHO’s megastudy of COVID-19 treatments - Sciencemag 16.10.20 247419
- Repurposed antiviral drugs for COVID-19 - interim WHO SOLIDARITY trial results - WHO 15.10.20 247420
- * Remdesivir for the Treatment of Covid-19 — Final Report - NEJM 08.10.20 247421
- Efficacy of chloroquine or hydroxychloroquine in COVID-19 patients: a systematic review and meta-analysis - JAC 08.10.20 226894
- Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19 - JAMA 02.09.20 215522
- Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19 - Jama Network 21.08.20 247422
- * Dexamethasone in Hospitalized Patients with Covid-19 — Preliminary Report - NEJM 17.07.20 229582
- Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19 - IDSA 11.04.20 247423
- A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19 - NEJM 18.03.20 201680
- Covid-19 — The Search for Effective Therapy - NEJM 18.03.20 201941
- The convalescent sera option for containing COVID-19 - JCI 13.03.20 201409
- More than 80 clinical trials launch to test coronavirus treatments - nature 15.02.20 247425
- Therapeutic options for the 2019 novel coronavirus (2019-nCoV) - Nature Reviews 10.02.20 247426
- Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro - Nature 04.02.20 247427
- Clinical management of severe acute respiratory infection when novel coronavirus (2019-nCoV) infection is suspected - WHO 28.01.20 247428